187 related articles for article (PubMed ID: 29508016)
1. Dual immuno-renal targeting of 7-benzylidenenaltrexone alleviates lupus nephritis via FcγRIIB and HO-1.
Tseng TC; Huang DY; Lai LC; Hwai H; Hsiao YW; Jhou JP; Chuang EY; Tzeng SJ
J Mol Med (Berl); 2018 May; 96(5):413-425. PubMed ID: 29508016
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of FcγRIIB by resveratrol via NF-κB activation reduces B-cell numbers and ameliorates lupus.
Jhou JP; Chen SJ; Huang HY; Lin WW; Huang DY; Tzeng SJ
Exp Mol Med; 2017 Sep; 49(9):e381. PubMed ID: 28960214
[TBL] [Abstract][Full Text] [Related]
3. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody.
Takeda Y; Takeno M; Iwasaki M; Kobayashi H; Kirino Y; Ueda A; Nagahama K; Aoki I; Ishigatsubo Y
Clin Exp Immunol; 2004 Nov; 138(2):237-44. PubMed ID: 15498032
[TBL] [Abstract][Full Text] [Related]
4. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
5. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
Sugahara K; Maeda Y; Shimano K; Murase M; Mochiduki S; Takemoto K; Kakimoto T; Utsumi H; Oshita K; Kataoka H
J Immunol Res; 2019; 2019():5821589. PubMed ID: 31930150
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.
Clynes R; Calvani N; Croker BP; Richards HB
Clin Exp Immunol; 2005 Aug; 141(2):230-7. PubMed ID: 15996187
[TBL] [Abstract][Full Text] [Related]
7. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
8. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.
Wu Y; He S; Bai B; Zhang L; Xue L; Lin Z; Yang X; Zhu F; He P; Tang W; Zuo J
Cell Mol Immunol; 2016 May; 13(3):379-90. PubMed ID: 25942599
[TBL] [Abstract][Full Text] [Related]
10. Heme supplementation ameliorates lupus nephritis through rectifying the disorder of splenocytes and alleviating renal inflammation and oxidative damage.
Wu B; Wu Y; Fan C; Feng C; Wang H; Bai F; Zuo J; Tang W
Int Immunopharmacol; 2021 May; 94():107482. PubMed ID: 33639567
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated heme oxygenase-1
Kishimoto D; Kirino Y; Tamura M; Takeno M; Kunishita Y; Takase-Minegishi K; Nakano H; Kato I; Nagahama K; Yoshimi R; Igarashi K; Aoki I; Nakajima H
Arthritis Res Ther; 2018 Apr; 20(1):64. PubMed ID: 29636091
[TBL] [Abstract][Full Text] [Related]
12. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
[TBL] [Abstract][Full Text] [Related]
14. Immune complex-mediated co-ligation of the BCR with FcγRIIB results in homeostatic apoptosis of B cells involving Fas signalling that is defective in the MRL/Lpr model of systemic lupus erythematosus.
Paunovic V; Carter NA; Thalhamer T; Blair D; Gordon B; Lacey E; Michie AM; Harnett MM
J Autoimmun; 2012 Dec; 39(4):332-46. PubMed ID: 22647731
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of FcγRIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus.
Sheng L; Cao X; Chi S; Wu J; Xing H; Liu H; Yang Z
Int J Mol Med; 2020 Oct; 46(4):1409-1422. PubMed ID: 32945349
[TBL] [Abstract][Full Text] [Related]
16. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
Anders HJ; Belemezova E; Eis V; Segerer S; Vielhauer V; Perez de Lema G; Kretzler M; Cohen CD; Frink M; Horuk R; Hudkins KL; Alpers CE; Mampaso F; Schlöndorff D
J Am Soc Nephrol; 2004 Jun; 15(6):1504-13. PubMed ID: 15153561
[TBL] [Abstract][Full Text] [Related]
17. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
Lenda DM; Stanley ER; Kelley VR
J Immunol; 2004 Oct; 173(7):4744-54. PubMed ID: 15383612
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
19. A benzenediamine derivate FC-99 attenuates lupus nephritis in MRL/lpr mice via inhibiting myeloid dendritic cell-secreted BAFF.
Ji J; Xu J; Li F; Li X; Gong W; Song Y; Dou H; Hou Y
Acta Biochim Biophys Sin (Shanghai); 2016 May; 48(5):411-9. PubMed ID: 27121231
[TBL] [Abstract][Full Text] [Related]
20. Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice.
Nowling TK; Rodgers J; Thiyagarajan T; Wolf B; Bruner E; Sundararaj K; Molano I; Gilkeson G
PLoS One; 2020; 15(3):e0230499. PubMed ID: 32187230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
